Innovation in pharma

OpinionSponsored
Health 12-12-2017

Drugs incentives have saved lives in Europe

Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.

Health 08-12-2017

Drug pricing debate to take place in heated atmosphere

Following a Greek government request, the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) will discuss on Friday (8 December) a recent dispute between Athens and ROCHE, a Swiss multinational company, over the latter’s decision to withdraw a cancer drug from the market.

Health 07-12-2017

Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped

Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.

Health 29-11-2017

UK and pharma industry call for transition period for medicines supply

With Brexit barely 15 months away, the UK government, as well as the European and British life science industry, is calling for a transition period on the regulation and supply of medicines in order to avoid potential disruptions in the market that will negatively affect patients.

Health 24-11-2017

Athens brings its dispute with pharma industry to the EU Council

The next EU Health Council on 8 December will discuss the “lack of drug availability in Greece”, amid mounting tensions between the leftist government in Athens and the pharmaceutical companies.

Health 24-11-2017

Andriukaitis: National health systems need ‘fundamental reform’

EU countries could save money and lives by increasing investment in disease prevention and health promotion, the European Commission said on Thursday (23 November), stressing that good health policy requires political will across all sectors.

Health 13-11-2017

EU health Commissioner Vytenis Andriukaitis discusses Europe’s superbug battlefront

Vytenis Andriukaitis, European Commissioner for Health and Food Safety, joined Brian Maguire to discuss Europe’s fight against the deadly rise of superbugs.

Health 10-11-2017

EMA relocation should consider the wellbeing of all Europeans

The competition for the European Medicines Agency is not a horse race but the first concrete, effective decision the EU has to make in the wake of Brexit - and one with long-lasting consequences. A responsible yet ambitious mindset is therefore in order, writes Sandro Gozi.

Health 02-11-2017

Pharmaceutical company gives free access to drug after clash with Greek government

Following a clash with the Greek government over its decision to withdraw a cancer drug from the market, ROCHE, a Swiss multinational company, ultimately decided to make the drug available to patients for free.

Health 31-10-2017

Greek health minister fumes at pharmaceutical company after drug withdrawal

The Greek ministry of health reacted strongly to the decision of a pharmaceutical company to withdraw a drug from the market for “viability” reasons, saying it will not accept any blackmail.

Health 30-10-2017

Pharmaceutical company withdraws oncology drug from Greek market

A multinational pharmaceutical company has decided to withdraw an innovative oncology medicine from the Greek market, claiming that its price has fallen more than 50% because of the government’s regulatory interventions in the pharma area, EURACTIV.com has learnt.

Health 25-10-2017

Greek government on collision course with pharmaceutical companies over innovative drugs

Several pharmaceutical companies in Greece have threatened to stop supplying the market with innovative drugs and said they could even withdraw existing drugs as a result of an obligatory “discount” imposed by the Greek government and applied retroactively.

Health 13-10-2017

New Commission study fuels generic drugs industry ‘manufacturing dispute’

The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.

Supporter